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A B S T R A C T   
Background and aims: Risk-factor identification and risk stratification are prerequisites to the effective primary 
and secondary prevention of cardiovascular disease (CVD). Patients at the highest risk benefit the most from the 
intensive risk-factor reduction. However, the high-risk patients’ group is heterogeneous, and it is increasingly 
recognised that there is an ‘extreme-risk’ category of patients who may require particularly close attention and 
intensive therapeutic approach. The aim of this study was to identify subgroups of patients at the highest risk of 
death following myocardial infarction (MI) that might be considered as those at extremely high CVD risk. 
Methods: We used data from 19,582 participants of the Hyperlipidaemia Therapy in tERtiary Cardiological 
cEnTer (TERCET) Registry (NCT03065543) of patients with ischaemic heart disease in Poland from 2006 to 
present. Characteristics of 13,052 patients with chronic coronary syndromes (CCS) were compared with those of 
4295 patients with myocardial infarction (STEMI and NSTEMI). Multivariable logistic regression with stepwise 
backward elimination was used to identify risk factors associated with mortality in the 12–36 months following 
the index hospitalisation. 
Results: The mortality rates were significantly higher in patients after MI than in patients with CCS. In the 
multivariable analysis, the risk factors most strongly associated with 12-month mortality in patients after MI 
were left ventricular ejection fraction (LVEF) lower than 35% (hazard ratio [HR] 3.83, 95% confidence interval 
[CI] 3.14–4.67), age >75 years (HR 1.91, 95%CI 1.55–2.35), multivessel coronary artery disease (HR 1.61, 95% 
CI 1.30–1.99), atrial fibrillation (HR 1.53, 95%CI 1.21–1.94) diabetes mellitus (HR 1.35, 95%CI 1.11–1.64) and 
increased LDL-C (HR per 1 mmol/l 1.09, 95%CI 1.01–1.19) or creatinine levels (HR per 10 μmol/L 1.04, 95% CI 
1.04–1.05). The risk factors that influenced mortality after 24–36 months were consistent with those after 12 
months, with additional low haemoglobin (20–25% risk increase per 1 mmol reduction) and chronic obstructive 
pulmonary disease (65% risk increase after 36 months). 
Conclusions: In our large, single-center real-world analysis, we identified the patients with the highest risk of 
death who could probably benefit the most from the most intensive therapy, and hence should be considered to 
be an ‘extreme risk’ population.  
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1. Introduction 
Despite significant improvements in the quality of care, cardiovas-
cular disease (CVD) remains the primary cause of death worldwide. In 
the European Union, CVD is responsible for 35% of deaths in women and 
men under the age of 75 years [1]. Moreover, it is predicted that in the 
coming decade, the number of disability-adjusted life years (DALY) lost 
due to CVD will increase from 169 million in 2020 to 187 million in 
2030 [2]. 
Despite sustained efforts to reduce the global burden of CVD, the 
prevalence of CV risk factors along with cardiovascular and non- 
cardiovascular comorbidities has continued to rise [3–5]. In 2016, the 
European Society of Cardiology (ESC) published the guidelines on CV 
prevention [6], in which the authors stratify the population into patients 
with low, intermediate, high, and very high-risk of death or CV event in 
a 10-year follow-up. Patients with previously diagnosed CVD (including 
coronary artery disease (CAD), peripheral artery disease (PAD), and 
history of stroke) are all assigned to the very high-risk group, without 
the need for further risk scoring, because of the demonstrated high 
event-rate in this group [6]. 
However, it is important to consider that the subgroup of patients at 
very high risk of CVD is very heterogeneous, and one could speculate 
whether it should be further subdivided in order to identify the patients 
within this group who are most likely to experience adverse outcomes. 
These individuals could be offered the most intensive, individualised 
treatment, considering starting with combination therapy in order to 
reduce the risk as quickly as possible. The American Association of 
Clinical Endocrinologists (AACE) and the American College of Endo-
crinology approached this problem in 2017, identifying an additional 
group of patients with so-called ‘extreme CV risk’ [7]. This subgroup 
included patients with progressive atherosclerotic CVD despite the 
achievement of LDL-C <1.8 mmol/L (<70 mg/dL) or established CVD 
with concomitant: DM, stage 3/4 of CKD and/or familial heterozygous 
hypercholesterolaemia (HeFH) or a history of premature atherosclerotic 
CVD defined as <55 years of age for males and <65 years of age for 
females [7]. In these patients, the authors recommend a more aggressive 
approach to the management of lipid disorders, suggesting a new 
threshold for LDL-C of 1.4 mmol/L (55 mg/dL) [7]. However, these 
guidelines are based solely on the recommendation of experts, therefore 
they do not strictly comply with the principles of evidence-based med-
icine (EBM). Moreover, the recently (2019) published mutual guidelines 
of the ESC and European Atherosclerosis Society (EAS) for the man-
agement of dyslipidaemias modified the therapeutic LDL-C targets to 
<1.4 mmol/L (55 mg/dL) in the very high-risk subgroup, and also made 
the first step to specify a group of patients at ‘extreme risk’. The authors 
of the guidelines recommend that reduction of LDL-C to <1 mmol/L (40 
mg/dL) should be considered in patients who experience a second 
vascular event in the two years following the first [8]. The definition of 
the extremely high-risk patients’ group has been next completed by the 
Polish experts in their most recent guidelines on laboratory diagnostics 
of lipid metabolism disorders, however, they based their definition 
mainly on the trials’ results with proprotein convertase subtilisin/kexin 
type 9 (PCSK9) inhibitors [9]. 
In our opinion, the criteria for inclusion in the ‘extreme-risk’ defi-
nition of the abovementioned guidelines do not encompass all relevant 
patients, especially considering the fact that patients following a 
myocardial infarction (MI) are not automatically included in the 
‘extreme cardiovascular (CV) risk’ group. The occurrence of MI is 
associated with substantially worse outcomes than other manifestations 
of CVD [10,11]. Based on the above, we aimed to identify subgroups of 
patients after myocardial infarction with the highest risk of death in a 
3-year follow-up. 
2. Patients and methods 
The design, rationale, and primary results from the Hyperlipidaemia 
Therapy in tERtiary Cardiological cEnTer (TERCET) Registry, along with 
the patient recruitment scheme, the definitions and methods of the long- 
term follow-up data gathering have been described in detail elsewhere 
[12–14]. In brief, the registry includes consecutive patients with all 
types of ischemic heart disease, hospitalised in a specialist supraregional 
center from 2006 to the present time. The entire population of the 
registry, which consists almost solely of patients of Caucasian race, 
meets the criteria of ‘very high’ CV risk as defined by the ESC guidelines 
[8]. All patients received detailed information about the aim of the 
registry and gave informed consent to participate in the analysis. The 
study was prospectively registered (NCT03065543). 
The aim of the registry is to evaluate the risk of adverse clinical 
events (death or recurrent cardiovascular events) as well as to assess the 
effectiveness of treatment, defined as achieving the therapeutic target of 
LDL-C level of <70 mg/dL (1.8 mmol/L) during the 12-month follow-up 
period (following the European Society of Cardiology (ESC)/European 
Atherosclerosis Society (EAS) 2016 guidelines for the treatment of lipid 
disorders) [15]. Data related to clinical events in the up to 36-month 
follow-up period were obtained from the National Health Fund and 
include: the date of death (cardiac/non-cardiac causes), non-fatal 
myocardial infarction, revascularization (either planned or following 
acute coronary syndrome - ACS) based on the following ICD-10 codes: 
I20.0, I21.0, I21.1, I21.2, I21.3, I21.4, I25.0, I25.2, I63.0 and I64.0. 
Detailed information on the medical history of patients is gathered 
and supervised by the physician in charge. The data are regularly 
updated and archived both manually and digitally. The system requires 
the completion of all data (including demographic data and laboratory 
test results) by the end of the hospitalisation. Records of ambulatory 
patients, who are treated in the hospital outpatient clinic after discharge 
from the hospital, are gathered and stored in the same way. 
Lipid profile parameters (concentrations of total cholesterol [TC], 
high-density lipoprotein cholesterol [HDL-C], LDL-C and triglycerides) 
were measured using the Cobas Integra 800 chemical auto-analyser 
(Roche Diagnostics, Switzerland). Triglyceride concentration was 
measured utilising the enzymatic-colourimetric method with glycerol-3- 
phosphate oxidase and 4-amino phenazone. TC, HDL-C, and LDL-C 
levels were measured directly using the homogenous colourimetric 
method based on a chain reaction between cholesterol esterase and 
oxidase, with the intensity of absorbance proportional to the change in 
colour of the specific pigment product concentration. 
2.1. Statistical analysis 
Basic parameters of descriptive statistics for the analysed continuous 
variables are presented as means and standard deviations (SD) if they 
are normally distributed, or otherwise as medians and the first and third 
quartiles (Q1-Q3). Normality of distribution was tested using the 
Shapiro-Wilk test. Between-group comparisons of continuous variables 
were conducted using Student’s t-test (if normally distributed); other-
wise, the Mann-Whitney U test was used. 
The Pearson’s chi-squared test was used to evaluate categorical 
variables. The interval of two-sided p < 0.05 was considered as statis-
tically significant. Unifactorial and multifactorial analyses were per-
formed to assess variables using the Cox proportional regression model 
or with the logistic regression (p < 0.1 for inclusion in the model, p <
0.05 for remaining in the model). All investigated clinical and angio-
graphic parameters that were statistically significant were included in 
the unifactorial analysis after the exclusion of co-dependent variables in 
the correlation analysis and can be found in Supplementary Table. 
Estimated parameter values are presented as hazard ratios (HR) with a 
95% confidence interval (CI). STATISTICA 10 (StarSoft Inc., Tulsa, OK, 
US) was used for all calculations. 
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3. Results 
3.1. Patients‘ characteristics 
At the time of the analysis, there were 19,582 patients included in 
the TERCET Registry. Among them, there were 4295 patients (21.9%, 
mean age 64.4 ± 11.5 years, women 32.0%) admitted due to acute 
myocardial infarction (2327 with ST-segment elevation myocardial 
infarction - STEMI, of whom women constituted 29.4% and 1968 pa-
tients with non-ST-segment elevation myocardial infarction - NSTEMI, 
of whom women constituted 34.7%). Patients with STEMI comprised 
11.9% of the population and their mean age was 62.7 ± 11.6 years, 
whilst patients with NSTEMI comprised 10.0% of the population with a 
mean age of 66.2 ± 11.2 years. In 2325 patients, unstable angina (UA) 
was diagnosed (11.9% of the population, mean age 65.2 ± 10.5 years, 
with 35.5% percentage of women). The remaining 13,052 patients were 
admitted with the chronic coronary syndrome (CCS, 66.7% of the pop-
ulation, mean age 64.5 ± 9.5 years, of whom 36.0% were female). The 
full baseline clinical and therapeutic profile of the entire TERCET pop-
ulation is presented in Table 1. 
In order to establish factors potentially associated with extreme risk 
of death in the 12–36 months following the index event, all patients with 
STEMI and NSTEMI diagnosis were included in the analysis. Therefore, 
the group constituted 4295 patients (54.2% with STEMI and 45.8% with 
NSTEMI). The clinical characteristics of the combined subgroup of 
TERCET patients with STEMI/NSTEMI are presented in Table 1. 
Patients admitted with MI differed significantly from those with CCS. 
There was a higher proportion of males in the MI group (68.0% vs 
64.0%, p < 0.001) and less prolific history of prior myocardial infarction 
or either type of revascularization procedure (26.7% vs 34.2% for MI, 
22.8% vs 32.1% for PCI and 7.4% vs 11.6% for coronary artery bypass 
graft surgery - CABG in respective groups, all p < 0.001). Furthermore, 
in patients with MI, the occurrence of PAD, hypertension, diabetes, 
hyperlipidaemia, atrial fibrillation (AF), and chronic obstructive pul-
monary disease (COPD) was significantly lower. Left ventricular ejection 
fraction (LVEF) was significantly lower (42,7 ± 10,2%) in patients with 
MI than in patients with CCS (46.5 ± 11.5%, p < 0.0001), and the 
percentage of patients with LVEF lower than 35% was 22.6% in patients 
after MI versus 17.9% in patients with CCS. 
Patients admitted due to MI had a higher prevalence (52.7% vs 
34.2%, p < 0.001) of multivessel coronary artery disease (MVD) on 
admission. The groups also differed with respect to treatments provided. 
A significantly higher proportion of patients admitted due to MI were 
treated with percutaneous coronary intervention (PCI), and the fre-
quency of coronary artery bypass graft surgery (CABG) performed in this 
population was significantly lower (89.4% vs 38.5% when PCI and 5.5% 
vs 9.2% when CABG were concerned, both p < 0.001). 
3.2. Extremely high-risk patients 
The patients with an acute MI had a significantly worse prognosis 
than those with CCS. The rates of all-cause mortality, recurrent MI, or 
repeat revascularization were approximately 3-fold higher, whilst the 
stroke occurred almost 2-fold higher in MI patients, as presented in 
Table 2. 
In order to assess the risk factors associated with worse outcomes in 
patients after MI, multivariate analysis with a stepwise backward 
regression model was performed. The all-cause mortality of MI patients 
Table 1 
Baseline clinical characteristics of the study population.  
Factor The TERCET registry N = 19,582 
CCS n = 13,052 UA n = 2235 NSTEMI n = 1968 STEMI n = 2327 Total MI n = 4295 p 
Age, years; mean (SD) 64.5 (9.6) 65.2 (10.5) 66.2 (11.2) 62.7 (11.6) 64.4 (11.5) <0.0001 
Males, % (n) 64 (8357) 64.5 (1269) 65.3 (1278) 70.6 (1642) 68.0 (2920) <0.0001 
Prior MI, % (n) 34.2 (4372) 46 (887) 36.2 (801) 17.6 (407) 26.7 (1208) <0.0001 
Prior PCI, % (n) 32.1 (4100) 49.1 (948) 34.6 (766) 11.6 (269) 22.8 (1035) <0.0001 
Prior CABG, % (n) 11.6 (1481) 17.3 (340) 12.6 (282) 2.5 (57) 7.4 (339) <0.0001 
Prior stroke, % (n) 5.6 (724) 5.7 (112) 6.5 (145) 1.5 (34) 3.9 (179) <0.0001 
Peripheral artery disease, % (n) 14.9 (1904) 12.8 (246) 13 (288) 1.5 (34) 7.1 (34) <0.0001 
Atrial fibrillation, % (n) 20.3 (2592) 14.6 (285) 14.6 (326) 7.8 (182) 11.1 (508) <0.0001 
Arterial hypertension, % (n) 80.0 (10,360) 84.7 (1644) 78.3 (1738) 53.7 (1249) 65.7 (2987) <0.0001 
Diabetes mellitus, % (n) 34.1 (4360) 39.7 (767) 39.5 (876) 21.2 (493) 30.1 (1369) <0.0001 
LVEF ≤35%, % (n) 17.9 (1610) 13.5 (246) 22.2 (483) 23.1 (514) 22.6 (514) <0.0001 
LDL-C, mmol/L (Q1-Q3) 2.44 (1.93–3.08) 2.50 (1.80–3.25) 2.71 (1.96–3.58) 3.00 (2.13–3.82) 2.85 (2.01–3.74) <0.0001 
HDL-C, mmol/L (Q1-Q3) 1.21 (1.00–1.50) 1.14 (0.98–1.40) 1.19 (0.93–1.45) 1.19 (0.98–1.47) 1.19 (0.96–1.46) <0.0001 
TG, mmol/L (Q1-Q3) 1.30 (0.97–1.79) 1.34 (0.95–1.88) 1.28 (0.88–1.81) 1.74 (0.82–1.66) 1.51 (0.85–1.72) <0.0001 
Cardiac arrest, % (n) 0.0 (0) 0.5 (9) 2.0 (44) 4.5 (105) 3.3 (149) <0.0001 
Killip III class, % (n) 0.6 (75) 0.6 (12) 2.4 (53) 2.9 (64) 2.7 (117) <0.0001 
Killip IV class, % (n) 0.0 (0) 0.2 (4) 1.3 (28) 8.0 (176) 4.6 (204) <0.0001 
LVEF, %; mean (SD) 46.5 (11.5) 47.1 (10.4) 43.2 (11.0) 42.1 (9.4) 42.7 (10.2) <0.0001 
Serum creatinine, μmol/L; median (Q1-Q3) 81 (68–96) 83 (70–100) 84 (70–103) 81 (68–98) 83 (69–100) <0.0001 
GFR <60 ml/min/1.73 m2, % (n) 17.4 (2260) 25.9 (574) 21.8 (423) 14.4 (336) 17.6 (759) <0.0001 
Multi-vessel CAD, % (n) 34.2 (4463) 40.8 (774) 57.1 (1231) 48.5 (1113) 52.7 (2344) <0.0001 
PCI, % (n) 38.5 (5026) 70.7 (1391) 80.6 (1802) 97.8 (2257) 89.4 (4059) <0.0001 
CABG, % (n) 9.2 (1200) 5.7 (113) 5.2 (117) 5.7 (132) 5.5 (249) <0.0001 
Acetylsalicylic acid, % (n)* 84.1 (9880) 89.3 (1742) 87.6 (1928) 98.3 (2149) 92.9 (4077) <0.0001 
P2Y12 receptor inhibitor, % (n)* 42.2 (4954) 74.1 (1445) 87.1 (1918) 95.9 (2096) 91.5 (4014) <0.0001 
Oral anticoagulant, % (n)* 20.7 (2435) 12.2 (237) 10.3 (226) 5.8 (132) 8.2 (358) <0.0001 
Beta-blocker, % (n)* 92.7 (10,888) 85.2 (1661) 83.5 (1838) 94.9 (2075) 89.2 (3913) <0.0001 
ACE inhibitor/ARB, % (n)* 84.6 (9935) 80.4 (1567) 77.4 (1705) 89.7 (1961) 83.5 (3666) <0.0001 
Statin, % (n)* 85.5 (9919) 92.9 (1754) 93.6 (1973) 94.8 (1619) 94.1 (3592) <0.0001 
Diuretic, % (n)* 51.6 (6054) 35.1 (684) 38.3 (844) 26.6 (619) 33.3 (1463) <0.0001 
Values presented as percentage (frequency) or means and standard deviation (SD) or median and inter-quartile range (Q1-Q3). ACE - angiotensin converting enzyme; 
ACS - acute coronary syndrome; ARB - angiotensin receptor blocker; CABG - coronary artery bypass grafting; CAD - coronary artery disease; CCS - chronic coronary 
syndrome; COPD - chronic obstructive pulmonary disease; GFR - glomerular filtration rate; HDL-C - high-density lipoprotein cholesterol; LDL-C - low-density lipo-
protein cholesterol; LVEF - left ventricular ejection fraction; NSTEMI - non-ST-segment elevation myocardial infarction; PCI - percutaneous coronary intervention;; 
STEMI - ST-segment elevation myocardial infarction; TG - triglycerides; UA – unstable angina. 
* Pharmacotherapy administered at discharge during the baseline hospital admission. 
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was respectively 12.1%, 16.1%, and 19.6% in the 12-month, 24-month, 
and 36-month follow-up. The following factors were most strongly 
associated with higher 12-month mortality in patients after MI (in order 
of decreasing hazard ratio): LVEF <35%, age >75 years, multivessel 
CAD, atrial fibrillation, diabetes mellitus, and increased LDL-C or 
creatinine levels (Fig. 1). In the 24-month analysis, the aforementioned 
risk factors remained significantly associated with mortality, while the 
reduction of haemoglobin levels at baseline was an additional inde-
pendent predictor of all-cause death (Fig. 2). Finally, at 36 months, the 
presence of chronic obstructive pulmonary disease (COPD) was next 
additional independent risk factor of all-cause mortality (Fig. 3). The 
sole factor independently improving survival in any analysed follow-up 
period (by 40%) was PCI performed in an acute phase of MI. The 
aggregate summary of risk factors, associated with extremely high risk, 
and hazard ratios for the 12-month, along with 24-month and 36-month 
all-cause death are presented in Figs. 1–3. 
Based on the definitions of extremely high-risk patients from the 
AACE and Polish Society of Laboratory Diagnostics (PSLD) and Polish 
Lipid Association (PoLA) guidelines, we analysed the risk of these 
specified populations and summarized the results in Table 3 [7–9]. The 
1-year mortality of patients with MI was 12.1%. The highest risk of 
all-cause death was observed in the subgroup with established CVD and 
concomitant: DM or stage 3/4 of chronic kidney disease (CKD) and/or 
heterozygous familial hypercholesterolaemia (18.3%) and in patients 
with progressive atherosclerotic CVD despite the achievement of LDL-C 
<70 mg/dL (16.0%). The 1-year mortality of the remaining subgroups 
was lower than in the overall MI cohort. 
4. Discussion 
In the large, single-center real-world registry encompassing almost 
20,000 patients with various manifestations of coronary artery disease, 
we showed that the mid- and long-term mortality rate was significantly 
higher in patients after MI, than in patients with CCS. The risk factors 
most strongly associated with higher 36-month mortality in patients 
after an MI were LVEF lower than 35%, age older than 75 years, atrial 
fibrillation, multi-vessel CAD, diabetes mellitus, increased LDL-C or 
creatinine, and decreased haemoglobin levels. The group of patients 
with these risk factors constitutes the population of the highest risk of 
death that should be considered to be the ‘extreme risk’ population. 
In 2016, in the USA alone, 550,000 ‘first in life’ and 200,000 
recurrent MIs were reported [16]. In Poland, the annual incidence of MI 
is approximately 85,000–90,000 [17]. Data from the national Polish 
PL-ACS registry, one of the largest registries in Europe, which encom-
passes patients with acute coronary syndromes, suggests that in-hospital 
mortality in patients with MI is 8.5%, and one-year mortality is 19.4% 
[17]. This overall dismal prognosis may be partially explained by the 
suboptimal organisation of post-MI care in Poland in the past. However, 
the prognosis for each individual depends on the presence of risk factors, 
comorbidities, and the method and intensity of their treatment [10–14]. 
We believe that an identification of patients at the highest risk could 
result in a more appropriate selection of the individuals requiring the 
most intensive pharmacological treatment. In the recent years, new 
evidence emerged indicating that therapy with new groups of drugs 
acting on various pathological pathways of cardiovascular disease, 
significantly reduced CV risk. The present analysis identified the CV risk 
factors independently increasing the risk of death after MI. Among those 
factors identified on admission to hospitalisation, those modifiable with 
the long-term secondary prevention strategies, included elevated levels 
of LDL-C, diabetes, hyperglycaemia, and atrial fibrillation. 
Two recent, large, randomized trials with PCSK9 inhibitors demon-
strated that in specific subgroups of patients, the treatment with those 
potent drugs resulted in a lower incidence of hard clinical endpoints [18, 
19]. More specifically, the absolute risk reduction of the composite 
endpoint (death from coronary artery disease, nonfatal MI, fatal or 
non-fatal ischaemic stroke, or unstable angina requiring hospitalisation) 
was 2% in the overall population studied in the ODYSSEY-Outcomes 
trial (number needed to treat - NNT of 49) [19,20]. However, based 
Table 2 
One-year outcomes of the study population.  
Factor The TERCET registry N = 19,582 
CCS n = 13,052 UA n = 2235 NSTEMI n = 1968 STEMI n = 2327 Total MI n = 4295 p 
Death, % (n) 4.8 (628) 5.5 (108) 12.3 (274) 12.0 (279) 12.1 (553) <0.0001 
MI, % (n) 2.1 (269) 5.2 (103) 9 (202) 5.5 (129) 7.3 (331) <0.0001 
ACS-driven revascularization, % (n) 2.2 (290) 8.7 (171) 9.3 (208) 4.3 (101) 6.8 (309) <0.0001 
Stroke, % (n) 1.0 (127) 1.1 (21) 2.0 (45) 1.5 (36) 1.8 (81) 0.0001 
ACS - acute coronary syndrome; CCS - chronic coronary syndrome; MI - myocardial infarction; NSTEMI - non-ST-segment elevation myocardial infarction; STEMI - ST- 
segment elevation myocardial infarction; UA – unstable angina. 
Fig. 1. Multivariate analysis of risk factors associated with 12-month mortality in patients with myocardial infarction. 
LDL-C, low-density lipoprotein cholesterol; LVEF – left ventricular ejection fraction; PCI – percutaneous coronary intervention, YO – years of age. 
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on the subgroup analyses of the trials with both evolocumab and alir-
ocumab, it was shown that for individuals with MVD, peripheral artery 
disease, or the history of multiple MIs, or statin intolerance, the clinical 
efficacy of the treatment with PCSK9 inhibitors were significantly 
higher, resulting in an NNT lower than 30 [21,22]. Therefore, the 
stratification of patients with the highest risk allows to determine those 
individuals who are most likely to benefit from more intensive 
lipid-lowering therapy [21,22]. 
It has been consistently demonstrated that the reduction of LDL-C 
levels is associated with a reduced risk of CVD [23]. The results of the 
available studies, in which either angiographic or clinical endpoints 
were assessed, demonstrate that the reduction of LDL-C should be one of 
the primary goals of CVD prevention [23,24]. A large meta-analysis of 
randomized-controlled trials of statin therapy demonstrated a 
dose-dependent reduction of relative CV risk. A reduction of LDL-C by 1 
mmol/L (38.6 mg/dl) is associated with an annual 20–25% reduced risk 
of CV death and non-fatal MI for every year, after the first year of 
treatment [25]. Furthermore, a recent meta-analysis supports further 
LDL-C reduction even in patients with very low LDL-C levels. It was 
demonstrated that the linear association between LDL-C and CV risk 
persists with a similar magnitude beyond <70 mg/dL [26]. 
Unfortunately, despite the presence of more effective lipid-lowering 
drugs and increasing numbers of patients being on more potent statins, 
the percentage of patients, who reach therapeutic target remains low 
(only 1/3 of patients in the Da Vinci Study) [27]. It is worth noting that 
in two large international European surveys conducted in patients who 
had undergone acute coronary syndrome or coronary revascularization, 
the percentage of patients who reached the therapeutic target of 1.8 
mmol/L did not exceed 30% [28,29]. 
Data from multiple studies indicate that patients with diabetes who 
experience MI have a more advanced coronary atherosclerosis and 
worse short- and long-term outcomes, than the non-diabetic MI patients 
[30–33]. The pooled results of the randomized trials, as well as from the 
Global Registry of Acute Coronary Events (GRACE) registry, indicate 
that in patients with either non-ST segment acute coronary syndrome 
(NSTE-ACS) or STEMI, risk of death at short- and medium-term fol-
low-up, is significantly higher in the presence of diabetes [32,34]. In the 
recent years, the results of the large, randomized trials have been pub-
lished, which demonstrated that the sodium-glucose co-transporter-2 
(SGLT-2) inhibitors, the new group of drugs for the treatment of 
Fig. 2. Multivariate analysis of risk factors associated with 24-month mortality in patients with myocardial infarction. 
LDL-C, low-density lipoprotein cholesterol; LVEF – left ventricular ejection fraction; PCI – percutaneous coronary intervention, YO – years of age. 
Fig. 3. Multivariate analysis of risk factors associated with 36-month mortality in patients with myocardial infarction. 
COPD – chronic obstructive pulmonary disease; LDL-C, low-density lipoprotein cholesterol; LVEF – left ventricular ejection fraction; PCI – percutaneous coronary 
intervention, YO – years of age. 
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diabetes, reduced the CV risk in patients of either high- or very-high CV 
risk, both with and without diabetes [35,36]. It should be noted that 
there are ongoing randomized trials evaluating the efficacy of SGLT-2 
inhibitors in patients after MI, but the preclinical studies and already 
published analyses from the other populations of patients suggest that 
these drugs might significantly improve outcomes in patients after MI. 
However, one should note that the SGLT-2 inhibitors were not widely 
available in Poland during the analysed period (due to lack of reim-
bursement) and almost none of the patients included in the study was 
treated with these drugs. 
Nonetheless, one has to acknowledge that the excessive CV risk is 
often a result of concomitant activity of atherosclerosis- and non- 
atherosclerosis related pathways, such as atrial fibrillation. Thus, the 
patients constituting this group might obtain a larger benefit from the 
more potent secondary prevention of recurrent ischemic events. Ac-
cording to the available data, AF is present in 5–23% of patients after MI 
[37]. In our population of patients with MI, the prevalence of AF was 
11%. It has previously been demonstrated that the subpopulation of 
patients with MI and AF has a significantly worse clinical profile and 
more comorbidities than other patients [38]. A recent subanalysis of the 
RE-DUAL PCI trial demonstrated that there was a significant overall 
benefit of dual antithrombotic therapy with dabigatran and either 
ticagrelor or clopidogrel over triple antiplatelet therapy with warfarin, 
aspirin and either ticagrelor or clopidogrel, in patients with atrial 
fibrillation and STEMI, which was similar to patients with NSTEMI, UA 
or CCS [39]. Similarly, as with SGLT-2 inhibitors, due to various reasons, 
including uncertainties with the reimbursement and high expensiveness 
of novel oral anticoagulants, only a small percentage of patients in our 
registry was treated with one of these drugs in the analysed period. 
Nevertheless, the factor most strongly associated with 1-year mor-
tality after MI was LVEF <35%. According to the literature, even more 
than 40% of patients discharged following MI have LVEF <35% [40]. In 
our analysis, reduced LVEF was associated with nearly 4-fold higher 
1-year mortality than in patients with normal LV contractility following 
an MI, and despite reduction in the hazard ratio over time, lower LVEF 
remained the most significant risk factor of higher mortality at 24 and 36 
months. 
In our opinion, patients with concurrent HF and CAD are substan-
tially underrepresented in the largest randomized clinical trials, such as 
The Improved Reduction of Outcomes: Vytorin Efficacy International 
Trial (IMPROVE-IT) and Further Cardiovascular Outcomes Research 
With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trials, 
where the symptoms of CHF were present in respectively 4.5% and 
13.5% of patients [18,19,23]. Moreover, the majority of patients 
included in the FOURIER trial had experienced MI more than three years 
before they were recruited into the study. This approach can lead to 
‘survivor bias’ resulting in a stable group of patients with relatively low 
residual risk compared to the overall population of post-MI patients. 
Because patients with low LVEF following MI are at such a high risk of 
mortality, they may derive more benefit from intensive secondary pre-
vention therapy than the general population of high-risk patients [41]. 
4.1. Limitations 
Our analysis is the retrospective assessment of the prospective reg-
istry and thereby cannot demonstrate causal relationships owing to re-
sidual confounding. Because the study included patients with only up to 
36-month follow-up, it was not possible to directly compare the out-
comes derived from our analysis with their risk predicted using the 
SCORE calculator, which predicts a 10-year mortality risk. Similarly, in 
our opinion the results of the present analysis are not comparable to the 
previously published risk scores such as TIMI, or SMART scores [42,43], 
which were performed in the different populations of patients, predict 
the CV risk in the different follow-up periods, and are not focused spe-
cifically on patients with an acute MI, who as demonstrated in our 
analysis, are at higher risk of death, than the overall cohort of patients 
with CVD. Moreover, the analysed population consists of inhabitants of a 
highly urbanized and polluted region. Although such environmental 
factors are not included in the major calculators of CV risk, they may 
significantly influence both short- and long-term outcomes [44–46]. It is 
worth mentioning that the population included in the study consists of 
patients burdened with multiple comorbidities and CV risk factors, who 
were treated in the single tertiary cardiovascular center, therefore the 
generalisability of the results to the more diverse populations might be 
limited. Moreover, despite being already established as an important CV 
risk factor significantly worsening prognosis in patients with CVD, 
almost none of the patients included in the present analysis had level of 
lipoprotein(a) measured, which therefore prohibits from analysing its 
association with outcomes of the studied population [47,48]. Further-
more, although our analysis included the assessment of various “extreme 
CV risk” subgroups defined previously, the single subgroup of patients, 
namely those who „experience a second vascular event in the two years 
following the first event” – was not available for analysis, due to the 
retrospective character of our registry and no information on the exact 
timing of the prior CV event. Finally, the retrospective character of our 
study allows one to observe the associations the analysed variables but 
prohibits from drawing the straightforward conclusions on the causality 
of the effects. 
4.2. Conclusions 
Patients with a history of MI have the highest risk of death in the 
whole spectrum of atherosclerotic coronary artery disease. This explains 
the inclusion of these patients in the ‘very-high CV risk’ subgroup as 
defined in the ESC guidelines. However, even within this group, there is 
a range of risk, with some patients more susceptible to recurrent events 
Table 3 
One-year mortality of patients defined as of extreme-risk in the AACE guidelines in the population of patients from the TERCET registry.  
Group Number of 
patients 
All-cause mortality in 12 
months 
Progressive atherosclerotic CVD despite the achievement of LDL-C <1.8 mmol/L (<70 mg/dL) 638 16.0% 
Established CVD with concomitant: DM, stage 3/4 of CKD and/or HeFH 1832 18.3% 
History of premature atherosclerotic CVD defined as <55 years of age for males and <65 years of age for females 225 5.9% 
Status post-ACS and the presence of peripheral artery disease or polyvascular disease (despite optimal treatment with maximum 
tolerated statin doses) 
103 10.7% 
Status post-ACS and coexistent multivessel coronary artery disease (despite optimal treatment with maximum tolerated statin 
doses) 
893 7.1% 
Status post-ACS and familial hypercholesterolaemia (FH) – despite optimal treatment with maximum tolerated statin doses 30 6.7% 
ACS - acute coronary syndrome CKD - chronic kidney disease; CVD - cardiovascular disease; DM - diabetes mellitus; FH - familial hypercholesterolaemia; HeFH - 
heterozygous familial hypercholesterolaemia; LDL-C – low-density lipoprotein cholesterol. 
The remaining groups of “extreme CV risk” patients are those, who "experience a second vascular event in the two years following the first event” - due to the character 
of our registry allowing us to determine the outcomes after the baseline hospitalisation, not before the event, the quantification of the risk in this subgroup was not 
possible. 
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than others. In our large, single-center, real-world analysis we identified 
factors that aggravated the mid- and long-term survival of patients 
initially stratified into ‘very-high CV risk’ population. These patients are 
expected to derive the most benefit from intensive secondary-prevention 
therapy, and hence should be considered to be an “extreme risk” 
population. 
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K. Dyrbuś et al.                                                                                                                                                                                                                                 
